Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

464 results
Display

Luteolin attenuates migration and invasion of lung cancer cells via suppressing focal adhesion kinase and non-receptor tyrosine kinase signaling pathway

Masraksa W, Tanasawet , Hutamekalin P, Wongtawatchai T, Sukketsiri W

BACKGROUND/OBJECTIVES: Non-small cell lung cancer is mostly recognized among other types of lung cancer with a poor prognosis by cause of chemotherapeutic resistance and increased metastasis. Luteolin has been found...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Genetic Characterization of Molecular Targets in Korean Patients with Gastrointestinal Stromal Tumors

Park J, Yoo HM, Sul HJ, Shin S, Lee SW, Kim JG

PURPOSE: Gastrointestinal stromal tumors (GISTs) frequently harbor activating gene mutations in either KIT or platelet-derived growth factor receptor A (PDGFRA) and are highly responsive to several selective tyrosine kinase inhibitors....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Inhibitory Effect of Rosae Multiflorae Fructus Extracts on the Receptor Activator of NF-κB Ligand-Induced Osteoclastogenesis through Modulation of P38- and Ca2⁺-Mediated Nuclear Factor of Activated T-Cells Cytoplasmic 1 Expression

Park KH, Gu DR, Kim MS, Lee SH

BACKGROUND: Rosae Multiflorae fructus (RMF), known to have anti-inflammatory and antioxidant properties, has been used as a traditional remedy for inflammatory diseases such as arthritis in Eastern Asia. However, its...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Current Status and Future Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest?

Lee HW, Cho KJ, Park JY

Most patients with hepatocellular carcinoma (HCC) are diagnosed at an advanced stage of disease. Until recently, systemic treatment options that showed survival benefits in HCC have been limited to tyrosine...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives

Lim SM, Hong MH, Kim HR

Immune checkpoint inhibitors (ICIs) have shown remarkable benefit in the treatment of patients with non-small-cell lung cancer (NSCLC) and have emerged as an effective treatment option even in the first-line...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Involvement of the TNF-α Pathway in TKI Resistance and Suggestion of TNFR1 as a Predictive Biomarker for TKI Responsiveness in Clear Cell Renal Cell Carcinoma

Hwang HS, Park YY, Shin SJ, Go H, Park JM, Yoon SY, Lee JL, Cho YM

BACKGROUND: Mechanism and predictive biomarkers for tyrosine kinase inhibitor (TKI) resistance of advanced clear cell renal cell carcinoma (ccRCC) have not been fully evaluated. METHODS: We performed gene expression profiling on...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Current Status of Immunotherapy for Lung Cancer and Future Perspectives

Kim HC, Choi CM

Lung cancer remains the most common cause of cancer-related deaths worldwide. Although there are many possible treatments, including targeted therapies such as epidermal growth factor receptor tyrosine kinase inhibitors and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Reviews on the Hepatotoxicity of Tyrosine Kinase Inhibitors

Han JM, Gwak HS

BACKGROUND: Small-molecule tyrosine kinase inhibitors (TKIs) have had major impacts on anticancer therapy by targeting the catalytic activities of dysregulated tyrosine kinases. TKIs have not presented traditional toxicities; however, some...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Prognostic Significance of Systemic Inflammatory Response in Patients with Synchronous and Metachronous Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors

Choi J, Kim TJ, Sung HH, Jeon HG, Jeong BC, Jeon SS, Lee HM, Choi HY, Kang M, Seo SI

PURPOSE: To determine whether systemic inflammatory response (SIR), particularly platelet-lymphocyte ratio (PLR) and neutrophil-lymphocyte ratio (NLR), has different prognostic role between patients with metastatic renal cell carcinoma (mRCC) receiving first-line...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Overcoming the Intrinsic Gefitinib-resistance via Downregulation of AXL in Non-small Cell Lung Cancer

Jeong I, Song J, Bae SY, Lee SK

BACKGROUND: Resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, is a limited factor in the treatment of non-small-cell lung cancer (NSCLC) patients. Therefore, ongoing studies...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Anti-cancer Activity of Paclitaxel, Lenvatinib and Radiation Combination Therapy on Anaplastic Thyroid Cancer in Vitro and in Vivo

Jun S, Kim SY, Kim SM, Park KC, Kim HJ, Chang HJ, Lee YS, Chang HS, Park CS

BACKGROUND/OBJECTIVES: Although anaplastic thyroid carcinoma (ATC) is rare, it is one of the deadliest forms of thyroid cancer. The fatality rate for ATC is high, and the survival rate at...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Severe Pneumocystis Pneumonia in a Thyroid Cancer Patient Receiving Lenvatinib

Jin MH, Kim WG, Kim TY, Kim WB, Shong YK, Jeon MJ

Lenvatinib is a multitargeted tyrosine kinase inhibitor approved for use in patients with iodine-131–refractory thyroid cancer. The common adverse events of lenvatinib include hypertension, proteinuria, fatigue, and diarrhea. To date,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Mouse Nerve Growth Factor Facilitates the Growth of Interspinal Schwannoma Cells by Activating NGF Receptors

Liu SY, Liu SZ, Li Y, Chen S

OBJECTIVE: Nerve growth factor (NGF) is a member of the neurotrophic factor family and plays a vital role in the physiological processes of organisms, especially in the nervous system. Many...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
RE-ORGA, a Korean Herb Extract, Can Prevent Hair Loss Induced by Dihydrotestosterone in Human Dermal Papilla Cells

Kang MG, Park D, Han HY, Shim H, Hong Y, Moon J, Yoon S, Kwon B

BACKGROUND: Androgenic alopecia (AGA) is the most common type of hair loss. It is likely inherited genetically and is promoted by dihydrotestosterone. 5α-reductase has been proven a good target through...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Current Development and Research Trend of Chemotherapeutic Agents for Head and Neck Squamous Cell Carcinoma

Lee YS

After FDA approval of cetuximab at 2006, receptor tyrosine kinase, including an epidermal growth factor receptor, blocking agents have been evaluated for head and neck squamous cell carcinoma (HNSCC). Agents...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Favorable long-term survival using consolidation chemotherapy without allogeneic hematopoietic cell transplantation for acute myeloid leukemia with wild-type NPM1 without FLT3-ITD

Baek DW, Lee JM, Kim JH, Cho HJ, Ham JY, Suh JS, Sohn SK, Moon JH

BACKGROUND: The role of allogeneic hematopoietic cell transplantation (allo-HCT) compared with consolidation chemotherapy alone in intermediate-risk acute myeloid leukemia (AML) patients with wild-type nucleophosmin/negative or a low level of Fms...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Contrast Enhanced Endoscopic Ultrasound Imaging for Gastrointestinal Subepithelial Tumors

Tamura T, Kitano M

Subepithelial tumors are divided into benign subepithelial and potentially malignant gastrointestinal stromal tumors. It is difficult to distinguish between these tumor types. Contrast-enhanced harmonic endoscopic ultrasound is reportedly useful for...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib

Kim S, Kim TM, Kim DW, Kim S, Kim M, Ahn YO, Keam B, Heo DS

PURPOSE: Amplified mesenchymal-epithelial transition factor, MET, is a receptor tyrosine kinase (RTK) that has been considered a druggable target in non-small cell lung cancer (NSCLC). Although multiple MET tyrosine kinase...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Chemotherapy for Lung Cancer in the Era of Personalized Medicine

Lee SH

Although recent advances in molecular targeted therapy and immuno-oncology have revolutionized the landscape of lung cancer therapeutics, cytotoxic chemotherapy remains an essential component of lung cancer treatment. Extensive evidence has...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Depigmentation in a Patient with Chronic Myeloid Leukemia during Chemotherapy with Dasatinib

Choi YW, Na N, Park J

  • KMID: 2451599
  • Korean J Dermatol.
  • 2019 Jun;57(5):292-293.
No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2023 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr